Reply to Peluso et al
To date, data on autoantibodies in patients post-COVID-19 are rare. Bhadelia et al [16] detected higher autoantibodies in their post-COVID-19 cohort when compared with controls. However, it has to be considered that the cohort of post-COVID-19 patients was very small (n = 9) and the samples were obt...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2022
|
| In: |
Clinical infectious diseases
Year: 2022, Volume: 74, Issue: 11, Pages: 2084-2085 |
| ISSN: | 1537-6591 |
| DOI: | 10.1093/cid/ciab892 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/cid/ciab892
|
| Author Notes: | Jessica Seeßle, Cord Naujokat, Phil Oberacker, Wolf-Henning Peters, Tim Waterboer, Barbara Müller, Uta Merle |
| Summary: | To date, data on autoantibodies in patients post-COVID-19 are rare. Bhadelia et al [16] detected higher autoantibodies in their post-COVID-19 cohort when compared with controls. However, it has to be considered that the cohort of post-COVID-19 patients was very small (n = 9) and the samples were obtained 1.8 to 7.3 months after acute infection. ANA titers have not been analyzed. Wallukat et al [17] revealed in 31 patients that long-COVID symptoms are associated with the detection of autoantibodies against G-protein-coupled receptors (GPCR) functionally active autoantibodies, which are supposed to play a role in the development of neurological and cardiovascular symptoms. In our recent publication, the proportion of patients having an ANA titer ≥1:160 at 5 and 12 months after acute infection was 40.6% and 43.6% of analyzed patients, respectively. |
|---|---|
| Item Description: | Gesehen am 10.11.2022 Published: 07 October 2021 |
| Physical Description: | Online Resource |
| ISSN: | 1537-6591 |
| DOI: | 10.1093/cid/ciab892 |